TG Therapeutics TGTX Q3 2025 Earnings Transcript

Image source: The Motley Fool.DateNov. 3, 2025 at 11:56 a.m. ETCall participantsChief Executive Officer — Michael WeissChief Commercial Officer — Adam WaldmanChief Financial Officer — Sean PowerNeed a quote from a Motley Fool analyst? Email [email protected]. BRIUMVI net sales -- $152.9 million, reflecting both sequential and year-over-year growth for the quarter.Total revenue -- $161.7 million, representing a 93% year-over-year increase and 15% sequential rise from fiscal Q2 2025 (pe...

TG Therapeutics: Positives From Q325 Earnings, But Competitors Progressing

Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million

Key PointsSold 21,000 shares of Check Point Software Technologies Ltd, an estimated $4.65 million trade in Q3 2025Post-trade stake: 0 shares, valued at $0The position previously accounted for 1.1% of fund AUM; now, CHKP is no longer held in the portfolioThese 10 stocks could mint the next wave of millionaires › On November 03, 2025, Hussman Strategic Advisors reported a full exit from Check Point Software Technologies Ltd. (NASDAQ:CHKP) in Q3 2025 with an estimated $4.65 million trade.What happe...

TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release

TG Therapeutics (TGTX) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line

TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.

TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release

TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel

TG Therapeutics: Estimates Could Soon Be Raised Again

Why TG Therapeutics Stock Was Tumbling Today

A near-doubling of revenue and a flip into profitability on the bottom line apparently werent good enough for TG Therapeutics (NASDAQ: TGTX) shareholders on Monday. The company, best known for its multiple sclerosis (MS) drug Briumvi, posted its first-quarter results that morning, and investors expressed their displeasure by trading out of the stock aggressively. In midafternoon action its price was down by more than 14%, comparing most unfavorably to the 0.2% dip of the S&P 500 index at that p...

TG Therapeutics stock sinks on profit miss

TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript

TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth

TG Therapeutics (TGTX) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TG Therapeutics Shares Rise Almost 30% in 3 Months: Heres Why

Strong adoption of TGTXs sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is driving the top line.

TG Therapeutics: Wie ein Rückschlag bei Roche dem US-Biotech neue Marktchancen bietet

Multiple Sklerose (MS) ist eine chronische Erkrankung des zentralen Nervensystems, bei der die Schutzhülle der Nervenfasern nach und nach beschädigt wird. Dadurch werden die Signale zwischen Gehirn und...

Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?

TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials

TG Therapeutics: Exciting Briumvi Performance, Looking To Re-Enter

Why TG Therapeutics Stock Was Soaring This Week

Following news of an estimates-topping fourth quarter, TG Therapeutics (NASDAQ: TGTX) stock was a hot item with investors over the past few days. According to data compiled by S&P Global Market Intelligence, as of mid-afternoon Friday, the biotechs share price had risen by almost 27% week to date. A fine fourth quarter TG Therapeutics got the ball rolling before the trading week kicked off, publishing its Q4 and full-year 2024 results Monday morning.Where to invest $1,000 right now? Our analyst...

TG Therapeutics soared 17% after earnings surprise

Here’s what happened to TG Therapeutics.

TG Therapeutics stock rises following upbeat Q4 earnings By Investing.com

TG Therapeutics stock rises following upbeat Q4 earnings

TG Therapeutics: Entering 2025 With Increased Investor Expectations

TG Therapeutics: 2025 Revenues Will Smash Expectations

TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last?

TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Presentation scheduled for Monday, January 13, 2025, at 4:30 PM PT Presentation scheduled for Monday, January 13, 2025, at 4:30 PM PT

TG Therapeutics to Participate in the Evercore HealthCONx Conference

Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET

TG Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript

TD Cowen sieht 102 % Kurspotenzial für TG Therapeutics Inc. (TGTX)

TG Therapeutics Inc. (TGTX) ist ein biopharmazeutisches Unternehmen, das sich auf innovative Therapien zur Behandlung von Autoimmun- und Krebserkrankungen spezialisiert hat. Neben einer Forschungspipeline...

TG Therapeutics: Die Briumvi Wachstumsstory bleibt durch neue Daten intakt

TG Therapeutics beschäftigt sich mit dem Erwerb, der Entwicklung und Vermarktung neuartiger Behandlungen für B-Zell-Malignome und Autoimmunerkrankungen. Das Unternehmen präsentierte Mitte September...

TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval